awmsg logo



linagliptin (Trajenta®)


Reference No. 1667

Publication date:
22/05/2013


Appraisal information

linagliptin (Trajenta®) 5 mg film-coated tablet


Company: Boehringer Ingelheim Ltd
BNF category: Endocrine system
NMG meeting date: 20/02/2013
AWMSG meeting date: 20/03/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0513
Ministerial ratification: 22/05/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Linagliptin (Trajenta®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; as combination therapy • in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control; • in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and • in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download